Accueil>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>Azide-PEG3-Tos

Azide-PEG3-Tos

Catalog No.GC65444

Azide-PEG3-Tos est un lieur PROTAC À base de PEG qui peut être utilisé dans la synthèse des PROTAC. Azide-PEG3-Tos est également un lieur PEG ADC À 3 unités non clivable utilisé dans la synthèse de conjugués anticorps-médicament (ADC).

Products are for research use only. Not for human use. We do not sell to patients.

Azide-PEG3-Tos Chemical Structure

Cas No.: 178685-33-1

Taille Prix Stock Qté
50mg
35,00 $US
En stock
100mg
54,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents

Azide-PEG3-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. Azide-PEG3-Tos is also a non-cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[2].

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[2].

[1]. Borchmann DE, et al. GRGDS-Functionalized Poly(lactide)-graft-poly(ethylene glycol) Copolymers: Combining Thiol-Ene Chemistry with Staudinger Ligation. Macromolecules. 2013 Jun 11;46(11):4426-4431.
[2]. Park, Tae Kyo, et al. Compound bearing beta-galactoside-introduced self-immolative linker. WO2018124758A2.

Avis

Review for Azide-PEG3-Tos

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Azide-PEG3-Tos

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.